MENU

Dumped: Blackmores (ASX:BKL) and Sirtex (ASX:SRX) exit the ASX100

The ASX released its latest quarterly update this morning, containing some major changes to the index’s composition.

Blackmores Limited (ASX: BKL) and Sirtex Medical Limited (ASX: SRX) have been dropped from the S&P/ASX 100 (ASX: XTO) (INDEXASX: ^AXTO) following the recent declines in their share price. Blackmores and Sirtex shares are down 39% and 45% respectively over the past year.

Elsewhere, there were plenty of other changes with Coca-Cola Amatil Ltd (ASX: CCL) and SEEK Limited (ASX: SEK) being dropped from the S&P/ASX 50 (ASX: XFL) (INDEXASX: ^AXFL). A2 Milk Company Ltd (Australia) (ASX: A2M) is being added into the S&P/ASX200 (ASX: XJO) (INDEXASX: ^AXJO) at the expense of OFX Group Ltd (ASX: OFX), which was dropped.

In and of itself, being added or removed from an index is little more than a reflection of how much a company’s share price has risen or fallen recently. Some companies, like Ausdrill Limited (ASX: ASL) are being added back to the index after being dropped in earlier times.

Being added or removed to an index can result in opportunities for shareholders however, as many funds have mandates that limit them to holding ASX100 or ASX200 shares, for example. Thus, being removed from an index would force funds to sell, and this can result in changes to prices – especially among smaller companies with lower trading volumes.

Blackmores in particular could see a sharp price decline, as it is a fairly illiquid company with only a small amount of shares on issue. A couple of others to keep an eye on for bargains could be Capitol Health Ltd (ASX: CAJ) and Lifehealthcare Group Ltd (ASX: LHC), although many of the companies being dropped appear to be due to actual business issues, not just increased pessimism among investors.

The following 3 companies are also a promising opportunity, in my opinion:

Top 3 Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often full franked..

But knowing which blue chips to buy, and when, can often be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Sean O'Neill owns shares of A2 Milk, LifeHealthcare Group Limited, and Sirtex Medical Limited. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

HOT OFF THE PRESSES: My #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.